Pawel Muranski

Pawel Muranski is a physician-scientist specializing in tumor immunology and T cell-based adoptive immunotherapy for cancer and viral infections.2 He currently holds several positions at Columbia University Medical Center:

Professional Roles

• Assistant Professor of Medicine, Pathology and Cell Biology34
• Principal Investigator at the Columbia Center for Translational Immunology (CCTI)3
• Director of Cellular Immunotherapy4

Research Focus

Dr. Muranski's work centers on:

1. Basic science of tumor immunology
2. Development of novel tumor- and virus-specific T cells for treating malignancies and refractory viral infections1

His research aims to initiate and execute early-phase clinical trials of adoptive immunotherapy at Columbia University Medical Center and NewYork-Presbyterian Hospital.

Notable Achievements

• Developed polyoma-virus specific T (PyVST) cells targeting John Cunningham (JC) virus-related Progressive Multifocal Leukoencephalopathy (PML)1
• Led a clinical trial of PyVSTs (NCT02694783) with promising results: 7/12 response rate and excellent safety record1

Laboratory

Dr. Muranski leads the Muranski Lab, which includes:

1. A basic/translational research unit
2. The Columbia Cellular Immunotherapy Laboratory (CITL), capable of clinical-grade manufacturing under current Good Manufacturing Practice (cGMP)1

His team explores various research areas, including the development of multi-epitope specific cytotoxic CD4+ T cells for treating cancers and refractory viral infections, as well as novel strategies for T cell-based therapy against SARS-CoV2 and related coronaviruses.1